Dimensional Fund Advisors LP Has $382.67 Million Holdings in Boston Scientific Corporation $BSX

Dimensional Fund Advisors LP grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 6.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,097,777 shares of the medical equipment provider’s stock after buying an additional 362,547 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Boston Scientific were worth $382,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in BSX. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at approximately $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. Bangor Savings Bank increased its stake in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Sfam LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth $29,000. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on BSX. BTIG Research reissued a “buy” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Tuesday, June 16th. Stifel Nicolaus reduced their price target on Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, June 25th. Raymond James Financial restated an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Truist Financial lowered their target price on shares of Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Finally, Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.84.

Boston Scientific Stock Down 1.4%

Shares of BSX opened at $43.14 on Wednesday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market capitalization of $64.12 billion, a P/E ratio of 18.05, a P/E/G ratio of 0.84 and a beta of 0.58. The company has a 50-day simple moving average of $47.77 and a 200-day simple moving average of $64.93.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.